GLPwatch
Papers (10410)
Page 138 of 174, ranked by citation count.
- Liraglutide modulates adhesion molecules and enhances cell properties in three-dimensional cultures of olfactory ensheathing cells.
- Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
- Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
- Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.
- Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice.
- An analysis of national news coverage of semaglutide for weight loss.
- Injectable drugs for weight management.
- <i>In vitro</i> cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems.
- Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.
- Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland.
- Obesity treatment as a bridge to solid organ transplantation: A comparison of bariatric surgery to medical therapy.
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
- Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.
- Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla.
- Association learning is impaired in insulin resistance and restored by liraglutide.
- Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1.
- More on Semaglutide in Early Type 1 Diabetes.
- Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
- Endoscopic and Open Carpal Tunnel Release in Patients With Type II Diabetes Mellitus: Influence of Preoperative Semaglutide Use on Postoperative Outcomes.
- GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.
- A Clinical Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists.
- Pneumoperitoneum by subcutaneous injections of GLP-1 analogues. A case report.
- In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
- Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
- Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?
- The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.
- Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.
- Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".
- GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.
- Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
- Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.
- Cardiovascular Outcomes Trials of Incretin-Based Therapies.
- [Diabetic ketoacidosis after switching insulin for exenatide].
- Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.
- Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning.
- Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.
- An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.
- Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
- Letter to Liu et al.'s "Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome".
- Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor.
- A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.
- TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE.
- Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
- Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.
- Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
- Exploring the nephroprotective effects of combined finerenone and exenatide therapy in diabetic nephropathy.
- Is it time to REWIND the cardiorenal clock in diabetes?
- Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.
- Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.
- The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care.
- Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
- New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
- Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
- A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
- Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
- Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.
- Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
- Semaglutide in weight management - Author's reply.